May & Baker

Last updated

May & Baker was a British chemical company founded by John May and William Gerrard Baker in Wandsworth, London in 1839. [1] They initially specialized in the manufacture of chemicals derived from mercury and bismuth. Over the years they diversified into other chemical fields including photographic chemicals, pharmaceuticals, agrochemicals, and chemicals for research and development.

Contents

The company was bought by Établissements Poulenc Frères (later to become Société des Usines Chimiques Rhône-Poulenc) in 1922, [2] and subsequently moved to Dagenham, Essex, although it continued to trade under the May & Baker name.

During this time May & Baker branched into pharmaceuticals, with one of their major discoveries being sulphapyridine (M&B 693), first produced in 1937. This compound, May & Baker's most famous product, was one of the first generation of sulfonamide antibiotics. During WW2, M&B 693 saved many thousands of lives, including Sir Winston Churchill who was treated with it for pneumonia infections twice during the war. In a subsequent wartime radio broadcast on December 29, 1943, he said: "This admirable M&B, from which I did not suffer any inconvenience, was used at the earliest moment; and after a week's fever, the intruders were repulsed." [3] The 693 numeric still features on the badge of May & Baker FC.

Post-war, May & Baker expanded into many countries round the world, particularly those in the Commonwealth, and comprised three divisions, Pharmaceuticals, Fine Chemicals and Agrochemicals. The 1960s were a boom time for the company, unofficially known as 'the Brittox Years' after one of its world-leading agrochemicals. There were agrochemical manufacturing sites in Sweet Briar Road, Norwich, Barton Moss in Manchester and Belvedere in Kent, a research station at Ongar in Essex and a head office at Regent House in nearby Brentwood.

The Agrochemical Division also contained Environmental Products (amenity horticulture) and Garden Care (retail), the latter being sold to Pan Britannica Industries (Sumitomo Group) in 1991. A subsidiary, Hortichem, was based in Ongar.

In 1986, a survey of the river bed sediments of the River Yare, near Norwich, Norfolk was undertaken by Imperial College, London, and showed significant pollution by mercury and copper with lesser amounts of cadmium, lead and zinc present. The pollution was traced to the May and Baker factory at Sweet Briar Road. [4]

In 1990 the company came under the direct supervision of Rhone-Poulenc, which later merged with Rorer, an American pharmaceutical company, to form Rhone-Poulenc Rorer.

In 1999 the company was split — the Dagenham site (now just pharmaceuticals), merged with Hoechst and changed the company name to Aventis, removing R&D from the site in July 2000. The Norwich site became part of Bayer Agrochemicals. The Nigerian subsidiary, bought out in 2002, remains as May & Baker Nigeria plc. [5]

Later on, a further merger with Sanofi-Synthélabo in 2004 changed the Dagenham site owner to Sanofi-Aventis. In 2009 Sanofi-Aventis announced their intention to close the Dagenham plant by 2013. [6] Sanofi's plans to turn the former site into a state-of-the-art science park were put in doubt by a lack of funding from London mayor Boris Johnson's Growth Fund. [7]

Club

The original works club still exists as The May & Baker Club, [8] and still uses the original M&B logo made using the old symbol for Mercury, surmounted with a five-pointed star. They also host a football club of the same name.

Related Research Articles

<span class="mw-page-title-main">Hoechst AG</span> German chemicals company

Hoechst AG was a German chemicals then life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiary of the resulting Sanofi-Aventis pharmaceuticals group.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

<span class="mw-page-title-main">Höchst (Frankfurt am Main)</span> Quarter of Frankfurt am Main in Hesse, Germany

Höchst is a quarter of Frankfurt am Main, Germany. It is part of the Ortsbezirk West.

<span class="mw-page-title-main">King Pharmaceuticals</span>

King Pharmaceuticals, is a pharmaceutical company, a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company. On October 12, 2010, King was acquired by Pfizer for $14.25 per share. King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin. They employed approximately 2,700 people including a sales force of over 1,000 individuals.

<span class="mw-page-title-main">Roussel Uclaf</span> French pharmaceutical company

Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi.

<span class="mw-page-title-main">Michel de Rosen</span>

Michel de Rosen is the chairman of Faurecia and was the CEO of Eutelsat Communications from 2009 to 2016. He is a non-executive member of the board of directors of ABB. He was chief executive officer and chairman of the board of directors of ViroPharma from August 2002 to May 2008. From 1982 to 1999, de Rosen held several positions at Rhône-Poulenc (France) and Rhone-Poulenc Rorer (USA), including chief executive officer from May 1995 until December 1999, and chairman of the board of directors from 1996 to 1999.

<span class="mw-page-title-main">Hospira</span> U.S. healthcare company

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines. It is one of four global producers of the yellow fever vaccine.

<span class="mw-page-title-main">Dalfopristin</span>

Dalfopristin is a semi-synthetic streptogramin antibiotic analogue of ostreogyrcin A. The combination quinupristin/dalfopristin was brought to the market by Rhone-Poulenc Rorer Pharmaceuticals in 1999. Synercid is used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

Roger Edward Collingwood Altounyan (1922–1987) was an Anglo-Armenian physician and pharmacologist who pioneered the use of sodium cromoglycate as a remedy for asthma. His family relocated to the United Kingdom where he studied medicine and started his pioneering research.

Rhône-Poulenc was a French chemical and pharmaceutical company founded in 1928. In 1999 it merged with Hoechst AG to form Aventis. As of 2015, the pharmaceutical operations of Rhône-Poulenc are part of Sanofi and the chemicals divisions are part of Solvay group and Bayer Crop Science.

Rhodia was a group specialized in fine chemistry, synthetic fibers, and polymers which was acquired by the Belgian Solvay group after a successful tender offer completed in September 2011. The company served the consumer goods, automotive, energy, manufacturing, and processes and electronics markets, and had 65 production sites worldwide, four research centers, and four joint laboratories.

Fisons plc was a British multinational pharmaceutical, scientific instruments and horticultural chemicals company headquartered in Ipswich, United Kingdom. It was listed on the London Stock Exchange and was once a constituent of the FTSE 100 Index. It was acquired by Rhone-Poulenc in 1995.

<span class="mw-page-title-main">Cassella</span>

Cassella AG, formerly Leopold Cassella & Co. and Cassella Farbwerke Mainkur AG, commonly known as Cassella, was a German chemical and pharmaceutical company with headquarters in Frankfurt am Main. Founded in 1798 in the Frankfurt Jewish Alley by Leopold Cassella, Cassella operated as an independent company until 1995 and was one of many predecessor companies of today's Sanofi. Its main products were dyes, drugs, cosmetics and various other chemical products. From 1949 Cassella focused increasingly on pharmaceuticals and cosmetics rather than its former primary focus, dyes. Much of its history is closely associated with the Gans family, a prominent family of industrialists and philanthropists and former owners of Cassella.

Hoechst Schering AgrEvo GmbH was a Düsseldorf-based limited liability company owned by Hoechst AG and Schering AG that only existed as an independent company for five years, from 1994 to 1999.

<span class="mw-page-title-main">Poulenc Frères</span>

Poulenc Frères was a French chemical, pharmaceutical and photographic supplies company that had its origins in a Paris pharmacy founded in 1827. From 1852 it began to manufacture photographic chemicals. It took the name Poulenc Frères in 1881, and by 1900 had a range of high-quality products. That year it went public as the Établissements Poulenc Frères. It began production of synthetic medicines, and continued to grow during World War I (1914–18). In 1928 it merged with the Société des usines chimiques du Rhône to form Rhône-Poulenc.

<span class="mw-page-title-main">Malika Haimeur</span> French engineer and chemist

Malika Haimeur is a French engineer and chemist and winner of the Irène Joliot-Curie Prize for Women & Business in 2009. She was named a Knight of the Legion of Honor in 2012.

References

  1. ↑ "May and Baker". www.gracesguide.co.uk.
  2. ↑ "History of Rhône-Poulenc S.A. – FundingUniverse". www.fundinguniverse.com.
  3. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 13 October 2007. Retrieved 28 December 2008.{{cite web}}: CS1 maint: archived copy as title (link)
  4. ↑ Sion, Charle E (1995). The behaviour of mercury and copper contamination in a lowland river system and their accumulation by some biota. Ph.D thesis, Imperial College, University of London.
  5. ↑ "May & Baker Nigeria Plc" . Retrieved 8 September 2011.
  6. ↑ "Sanofi pulls out of Dagenham". pharmafile. Retrieved 5 May 2014.
  7. ↑ "Sanofi's Dagenham Science Park legacy in turmoil as Boris Johnson denies funding". Barking and Dagenham Post. 29 November 2013. Retrieved 5 May 2014.
  8. ↑ "M&B". www.mayandbakersclub.co.uk.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.